Spots Global Cancer Trial Database for tuberous sclerosis complex
Every month we try and update this database with for tuberous sclerosis complex cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II | NCT06392009 | Tuberous Sclero... Focal Cortical ... | Radiprodil | 6 Months - 18 Years | GRIN Therapeutics, Inc. | |
| The Cognitive Variability in NF1 and TSC Monozygotic Twins | NCT02436746 | Neurofibromatos... Tuberous Sclero... | - | Erasmus Medical Center | ||
| Lymphangioleiomyomatosis, a Study on Cathepsin K | NCT05323370 | Lymphangioleiom... Tuberous Sclero... | 24h urine urine sample | 18 Years - | University Hospital, Tours | |
| Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC) | NCT02635789 | Tuberous Sclero... Angiofibroma Hypomelanotic M... Plaque | NPC-12G gel Placebo gel | 3 Years - | Nobelpharma | |
| Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) | NCT00790400 | Tuberous Sclero... Lymphangioleiom... | Everolimus (RAD... Everolimus Plac... | 18 Years - | Novartis | |
| Everolimus for Cancer With TSC1 or TSC2 Mutation | NCT02201212 | TSC1 TSC2 Tuberous Sclero... MTOR | Everolimus | 18 Years - | Dana-Farber Cancer Institute | |
| Studies in Patients With Tuberous Sclerosis Complex | NCT03276195 | Tuberous Sclero... | - | Translational Genomics Research Institute | ||
| A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD | NCT02451696 | Epilepsy Tuberous Sclero... Focal Cortical ... | Everolimus | 2 Years - 40 Years | NYU Langone Health | |
| Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC | NCT01767779 | Tuberous Sclero... | 1 Day - 6 Months | University of Alabama at Birmingham | ||
| Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution | NCT05044819 | Lennox Gastaut ... Dravet Syndrome Tuberous Sclero... | Cannabidiol | 1 Year - | Jazz Pharmaceuticals | |
| Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry) | NCT06160310 | Tuberous Sclero... Lymphangioleiom... | - | Children's Hospital Medical Center, Cincinnati | ||
| Topical Rapamycin and Calcitriol for Angiofibroma of Tuberous Sclerosis | NCT03140449 | Facial Angiofib... | Rapamycin Calcitriol Rapamycin-calci... | 7 Years - 65 Years | National Taiwan University Hospital | |
| Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry) | NCT06160310 | Tuberous Sclero... Lymphangioleiom... | - | Children's Hospital Medical Center, Cincinnati | ||
| A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML) | NCT05252585 | Renal Angiomyol... | Everolimus | 20 Years - 65 Years | Novartis | |
| Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex | NCT02849457 | Tuberous Sclero... | Vigabatrin Placebo | 1 Day - 6 Months | University of Alabama at Birmingham | |
| Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy | NCT05323734 | Tuberous Sclero... | Ganaxalone Placebo | 1 Year - 65 Years | Marinus Pharmaceuticals | |
| Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study | NCT05104983 | Tuberous Sclero... Epilepsy | Sirolimus Placebo | 1 Day - 6 Months | Children's Hospital Medical Center, Cincinnati | |
| Biomarkers for Tuberous Sclerosis Complex (BioTuScCom) | NCT02654340 | Hypomelanotic M... Facial Angiofib... Shagreen Patche... Ungual Fibromas Cortical Dyspla... Cardiac Rhabdom... Lymphangioleiom... Renal Angiomyol... Subependymal Gi... | 2 Years - 50 Years | CENTOGENE GmbH Rostock | ||
| The Effectiveness and Safety of Vagus Nerve Stimulation for TRE | NCT04198207 | Tuberous Sclero... Epilepsy | 2 Years - | Beijing Children's Hospital | ||
| Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants | NCT04595513 | Tuberous Sclero... Epilepsy | TAVT-18 (siroli... | 1 Day - 6 Months | Children's Hospital Medical Center, Cincinnati | |
| Acceptance and Commitment Therapy in Tuberous Sclerosis Complex | NCT05867576 | Tuberous Sclero... | Acceptance and ... | 11 Years - 24 Years | University Hospitals Bristol and Weston NHS Foundation Trust | |
| Placebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis Complex | NCT05534672 | Tuberous Sclero... | Rapamycin Placebo | 3 Months - 50 Years | Children's Memorial Health Institute, Poland | |
| Feasibility of [11C]Acetate-PET in LAM and TSC | NCT05467397 | Lymphangioleiom... Tuberous Sclero... | [11C]acetate | 18 Years - | Brigham and Women's Hospital | |
| Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex | NCT01730209 | Tuberous Sclero... TSC Related Cog... TSC Related Aut... TSC Related Lea... | Everolimus Placebo | 4 Years - 15 Years | Erasmus Medical Center | |
| A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML) | NCT05252585 | Renal Angiomyol... | Everolimus | 20 Years - 65 Years | Novartis | |
| A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD | NCT02451696 | Epilepsy Tuberous Sclero... Focal Cortical ... | Everolimus | 2 Years - 40 Years | NYU Langone Health | |
| Biomarkers for Tuberous Sclerosis Complex (BioTuScCom) | NCT02654340 | Hypomelanotic M... Facial Angiofib... Shagreen Patche... Ungual Fibromas Cortical Dyspla... Cardiac Rhabdom... Lymphangioleiom... Renal Angiomyol... Subependymal Gi... | 2 Years - 50 Years | CENTOGENE GmbH Rostock | ||
| Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex | NCT03356769 | Tuberous Sclero... Aspirin Epilepsy Cognitive Decli... Skin Lesions | Aspirin AED Placebo | 6 Years - 30 Years | Peking Union Medical College Hospital | |
| Dermatologic Patterns of Tuberous Sclerosis Patients and Somatic Mutation Relationship | NCT04112537 | Tuberous Sclero... | - | University Hospital, Montpellier | ||
| Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC | NCT05495425 | Tuberous Sclero... | NPC-12Y gel NPC-12Y placebo... | 3 Years - | Nobelpharma | |
| Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex | NCT02098759 | TSC Tuberous Sclero... Epilepsy | epilepsy early ... | - 4 Months | Children's Memorial Health Institute, Poland | |
| Topical Rapamycin and Calcitriol for Angiofibroma of Tuberous Sclerosis | NCT03140449 | Facial Angiofib... | Rapamycin Calcitriol Rapamycin-calci... | 7 Years - 65 Years | National Taiwan University Hospital | |
| Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex | NCT03356769 | Tuberous Sclero... Aspirin Epilepsy Cognitive Decli... Skin Lesions | Aspirin AED Placebo | 6 Years - 30 Years | Peking Union Medical College Hospital | |
| Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC | NCT01767779 | Tuberous Sclero... | 1 Day - 6 Months | University of Alabama at Birmingham | ||
| Studies in Patients With Tuberous Sclerosis Complex | NCT03276195 | Tuberous Sclero... | - | Translational Genomics Research Institute | ||
| Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study | NCT05104983 | Tuberous Sclero... Epilepsy | Sirolimus Placebo | 1 Day - 6 Months | Children's Hospital Medical Center, Cincinnati | |
| Safety of Simvastatin in LAM and TSC | NCT02061397 | Lymphangioleiom... Tuberous Sclero... | Simvastatin Sirolimus Oral ... Everolimus Oral... | 18 Years - | University of Pennsylvania | |
| Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures | NCT04485104 | Seizure in Part... Seizure in Part... Seizure in Part... | GWP42003-P | 1 Month - 23 Months | Jazz Pharmaceuticals | |
| Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis Complex | NCT02634931 | Tuberous Sclero... Angiofibroma Hypomelanotic M... Plaque | NPC-12G gel | 3 Years - | Nobelpharma | |
| Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy | NCT05604170 | Tuberous Sclero... | Ganaxolone | 1 Year - 65 Years | Marinus Pharmaceuticals | |
| Early Biomarkers of Autism in Infants With Tuberous Sclerosis Complex (TSC) | NCT01780441 | Tuberous Sclero... | 3 Months - 12 Months | Boston Children's Hospital | ||
| Rapalogues for Autism Phenotype in TSC: A Feasibility Study | NCT01929642 | Tuberous Sclero... Self-injury Autism | Sirolimus Everolimus | 2 Years - 30 Years | Hugo W. Moser Research Institute at Kennedy Krieger, Inc. | |
| Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC) | NCT02635789 | Tuberous Sclero... Angiofibroma Hypomelanotic M... Plaque | NPC-12G gel Placebo gel | 3 Years - | Nobelpharma | |
| Biomarkers for Tuberous Sclerosis Complex (BioTuScCom) | NCT02654340 | Hypomelanotic M... Facial Angiofib... Shagreen Patche... Ungual Fibromas Cortical Dyspla... Cardiac Rhabdom... Lymphangioleiom... Renal Angiomyol... Subependymal Gi... | 2 Years - 50 Years | CENTOGENE GmbH Rostock | ||
| Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC) | NCT02461459 | Tuberous Sclero... Autism Disorder Intellectual Di... | 18 Months - | Boston Children's Hospital | ||
| Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC) | NCT02635789 | Tuberous Sclero... Angiofibroma Hypomelanotic M... Plaque | NPC-12G gel Placebo gel | 3 Years - | Nobelpharma | |
| Basimglurant in Children, Adolescents, and Young Adults With TSC | NCT05059327 | Tuberous Sclero... | Basimglurant wi... Placebo with cr... | 5 Years - 30 Years | Noema Pharma AG |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
